Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer, has executed a purchase and sale agreement to acquire 10.7 acres of land adjacent to their facility in Spokane, WA.
 
The company specializes in the manufacture (fill and finish) of injectable drugs, including vaccines and biological therapeutics. The campus expansion will support Selkirk’s growth and add critically needed capacity for the manufacture of commercial and clinical trial drugs.
 
“Spokane is a special place to live, work, and invest,” said Patrick Haffey, CEO, Selkirk. “We are grateful to be here and plan to make a series of long-term investments in this community over the coming years.”
 
The land acquisition expands the Selkirk campus to more than 27 acres, providing space for three standalone factories. Selkirk’s Plant 1, a state-of-the-art, 145,000 square foot facility located at 9110 W. Granite Ave, is under construction and will be complete in March of 2022.
 
Selkirk and its partners have so far invested over $90 million and will announce additional investments to build out the remaining campus at a later date. All three Selkirk factories will incorporate industry-leading technology, including isolator-based filling systems and electronic batch records.
 
Selkirk has 35 employees and is actively recruiting to support the start of Plant 1 operations in mid-2022. At full capacity, the Selkirk campus is expected to employ roughly 750 scientists, engineers, and operations personnel.